The last few weeks have been historic in the fight against cancer. Novartis got approval for the first treatment in a revolutionary new class of drugs, shortly after Gilead Sciences Inc. spent $11.9 billion on a biotech company working in the field. Neither can rest on its laurels. Research in the field is moving so fast that today’s breakthroughs can easily become tomorrow’s has-beens. “I can’t think of any other therapies in oncology that have seen such rapid development,” said Rachel Webster, senior director of oncology at Decision Resources Group, a health care research and consulting firm in London.
NYS Entity Status
NYS Filing Date
NOVEMBER 06, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - ESR DEVELOPMENT CONSULTANTS INC.
2013 - RFP DEVELOPMENT CONSULTANTS, INC.
Around the Web
- Cancer drug research moving fast in immunotherapy field
By Michelle Fay Cortez - Tuesday Sep 5, 2017
- Mobile Games Rethink Ads: Roadblock or Reward?
Sunday Aug 20, 2017
Mobile developers such as Activision Blizzard Inc.’s King Digital have stopped resisting in-game ads and are ringing up revenue gains with messages from companies like Nestlé SA and Visa Inc.
- Time Inc. Launches 'People Perks' Membership for Product Discounts
Wednesday Sep 27, 2017
Time Inc. is offering memberships for $60 per year or $5.99 per month that give consumers access to deals on products related to entertainment, beauty, food, pets and more. It’s part of wider efforts to develop new revenue sources.
- Lyft to Develop Self-Driving Car Technology in New Silicon Valley Facility
By MIKE ISAAC - Friday Jul 21, 2017
The ride-hailing company is opening a research center in Palo Alto, Calif., and plans to collaborate with automakers and tech companies.
- New Development: Soft in the Middle, Splashy Up Top
By STEFANOS CHEN - Friday Sep 15, 2017
The luxury market in New York is pulling in two directions, with developers betting on big-ticket palatial aeries and million-dollar “starter” homes.